# Advancing antifungal therapy: exploring targeted CFW-PEc-enhanced ethosomal formulations of amphotericin B against cryptococcal pneumonia

## TL;DR

Researchers developed a new targeted nanodrug delivery system to improve amphotericin B's effectiveness and safety in treating cryptococcal pneumonia.

## Contribution

The novel use of CFW-PEc conjugates in ethosomes enhances antifungal efficacy and reduces toxicity of amphotericin B.

## Key findings

- CFW-PEc-AmB-ethosomes showed superior antifungal activity with reduced cytotoxicity in vitro.
- In vivo studies showed a 10-fold reduction in fungal burden and improved lung histopathology in mouse models.
- The formulation effectively targets Cryptococcus neoformans while preserving pulmonary architecture.

## Abstract

Cryptococcus neoformans is a significant and pathogenic
encapsulated basidiomycete fungus responsible for cryptococcosis,
particularly in immunocompromised individuals. With increasing incidence
rates globally, there is an urgent need for improved therapeutic strategies.
This study presents the development of a fungal-targeted nanodrug delivery
system utilizing a calcofluor white-phosphatidylethanolamine conjugate
(CFW-PEc) to enhance the delivery and efficacy of amphotericin B against
C. neoformans. We successfully formulated AmB-loaded
CFW-PEc-ethosomes, which demonstrated favorable physicochemical properties,
including suitable particle size, zeta potential, and high drug entrapment
efficiency. In vitro antifungal assessments revealed that
CFW-PEc-AmB-ethosomes exhibited superior antifungal activity compared to
conventional AmB formulations, maintaining high inhibition rates at lower
concentrations, while also demonstrating a favorable safety profile with
reduced cytotoxicity. Additionally, in vivo studies in a
mouse model of cryptococcal pneumonia illustrated remarkable reductions in
fungal burdens and improved histopathological outcomes, attributing these
effects to effective targeting of C. neoformans via
CFW-PEc. Our findings underscore the potential of CFW-PEc in enhancing the
therapeutic efficacy and safety profile of antifungal treatments, paving the
way for advanced treatment strategies against cryptococcal pneumonia.

Cryptococcal pneumonia presents a significant global health burden with
limited therapeutic options due to inherent toxicity and suboptimal
bioavailability of conventional antifungal agents. This investigation
demonstrates the innovative application of calcofluor
white-phosphatidylethanolamine conjugate (CFW-PEc) to enhance amphotericin B
(AmB) delivery via ethosomes for cryptococcal infection treatment. Our
findings elucidate that CFW-PEc significantly potentiates the antifungal
efficacy of AmB-loaded ethosomes against Cryptococcus
neoformans while concomitantly mitigating associated
cytotoxicity at optimal concentrations. In murine models of pulmonary
cryptococcosis, this novel formulation achieved a remarkable 10-fold
reduction in fungal burden compared to controls, while preserving pulmonary
histoarchitecture and attenuating inflammatory responses. This delivery
system’s integrated strategy of increasing antifungal effectiveness
while reducing adverse effects marks a significant leap forward in
developing safer and more targeted nanomaterial-mediated antifungal
treatments. These results have profound implications for developing more
efficacious and less toxic treatment modalities for cryptococcal pneumonia
and potentially other invasive fungal infections.